01—Abstract
Summary
Summary of the 10-Q filed May 7, 2025. Cited figures are marked; the original filing is the authoritative source.
Revolution Medicines, Inc. reported a net loss of $213.4 milliona for the three months ended March 31, 2025, compared with $116.0 million in the prior-year period.
Research and development expenses rose to $205.7 millionb from $118.0 million, driven mainly by daraxonrasib, zoldonrasib and elironrasib clinical trial and manufacturing costs, higher headcount and stock-based compensation. General and administrative expenses increased to $35.0 million from $22.8 million. The accumulated deficit reached $2.0 billion, and total stockholders' equity was $2.08 billion at March 31, 2025.
As of March 31, 2025, the company held $2.1 billionc in cash, cash equivalents and marketable securities, including $333.6 million of cash and cash equivalents and $1.77 billion of marketable securities. Management believes these resources will fund planned operations for at least 12 months following the filing date. The filing states the company will require substantial additional financing for its development efforts and has no committed external source of funds.
No shares were sold under the 2024 at-the-market program during the quarter. The filing describes the company's pipeline of RAS(ON) inhibitors. The Phase 3 RASolute 302 trial of daraxonrasib in second-line pancreatic cancer is ongoing, with an expected clinical readout in 2026, and the RASolve 301 non-small cell lung cancer trial is being activated.
The company also disclosed updated clinical data for daraxonrasib, elironrasib and zoldonrasib on May 7, 2025, as described in the filing. The company reports no product revenue and expects operating losses to continue.
02—Key points
Key Highlights
- Net loss of $213.4 million for Q1 2025, up from $116.0 million in Q1 2024; net loss per share of $1.13 versus $0.70.
- Research and development expense rose to $205.7 million from $118.0 million, led by a $40.5 million increase in daraxonrasib costs and a $12.5 million increase in zoldonrasib costs.
- General and administrative expense increased to $35.0 million from $22.8 million, including higher salaries and pre-commercial development expenses.
- Cash, cash equivalents and marketable securities totaled $2.1 billion at March 31, 2025, versus $2.3 billion at December 31, 2024; operating cash outflow was $194.4 million for the quarter.
- Accumulated deficit reached $2.0 billion; the company has never generated product revenue.
- Phase 3 RASolute 302 trial of daraxonrasib in second-line pancreatic cancer is ongoing with an expected readout in 2026; RASolve 301 in NSCLC is being activated.
- Pending Nemeth v. Casdin Delaware lawsuit tied to the 2021 EQRx merger; the company does not believe it will have a material adverse impact.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed May 7, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| R&D Expenses | $205.75M$118.02M | +74.3% |
| Operating Expenses | $240.76M$140.86M | +70.9% |
| Operating Income | -$240.76M-$140.86M | −70.9% |
| Net Income | -$213.42M-$116.00M | −84.0% |
| EPS (Basic) | $-1.13$-0.70 | −61.4% |
| EPS (Diluted) | $-1.13$-0.70 | −61.4% |
| Shares Outstanding (Basic) | 188.15M164.73M | +14.2% |
| Shares Outstanding (Diluted) | 188.15M164.73M | +14.2% |
05—Questions
Frequently Asked Questions
How much cash runway does Revolution Medicines have?
As of March 31, 2025, the company had $2.1 billion in cash, cash equivalents and marketable securities. Management believes these resources will enable it to fund planned operations for at least 12 months following the filing date. The filing also states the company will require substantial additional financing and has no committed external funding source.
What drove the increase in operating expenses?
Research and development expenses increased by $87.7 million, primarily from higher daraxonrasib clinical trial and manufacturing costs ($40.5 million increase), zoldonrasib expenses ($12.5 million increase), employee-related costs ($12.0 million increase) and elironrasib expenses ($9.1 million increase). General and administrative expenses rose $12.2 million, mainly from salaries, pre-commercial development and stock-based compensation.
What are the key near-term clinical milestones?
The RASolute 302 Phase 3 trial of daraxonrasib in second-line metastatic pancreatic ductal adenocarcinoma is expected to substantially complete enrollment in 2025, with a clinical readout expected in 2026. The company also expects to initiate Phase 3 monotherapy studies of daraxonrasib in first-line metastatic PDAC and in adjuvant resectable PDAC in the second half of 2025.
Has the company raised capital recently, and does it plan to?
In December 2024, the company completed an underwritten offering with net proceeds of $823.0 million. No shares were sold under the 2024 at-the-market program during the first quarter of 2025. The filing states the company expects to finance cash needs through a combination of equity and debt offerings, collaborations, licensing and other arrangements, and may seek capital in favorable market conditions.
06—Continue